Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]
Impact of Anti-Endothelial Cell Antibodies in Patients with Polycythemia Vera and Thrombosis
Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested. A new analysis of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera (PV) suggests that autoimmunity may be one mechanism by which thrombosis develops. Abstract Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are responsible for thrombosis. JAK2V617F causes inflammation […]
Ten Year Anniversary Living with Polycythemia Vera Blood Cancer
Inspire by Living! by David Wallace Your numbers do NOT always reflect how you feel, so important to remember! I’ve felt like crap before and my numbers were good. How you feel is one of the most important measurement criteria, in my opinion. Counts were off on my last heme visit, about a month ago, […]
Questions to Ask your Doctor for a PV Appointment
By David Wallace Updated September 10, 2026 The most useful questions to ask your doctor about polycythemia vera cover your diagnosis, blood count goals, symptoms, treatment choices, and what to do between visits. Bring a short written list, start with your biggest concerns, and leave with a plan you understand. Our new Polycythemia Vera Guide […]
